;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Aegerion to raise $250M in notes

    Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) said it plans to raise $250 million through the sale of senior convertible notes due in 2019. Last month, the company reported $36 million in 2Q14 net product sales of …

    Published on 8/11/2014
  • FINANCIAL NEWS: Danish Forward Pharma files for IPO

    Forward Pharma A/S (Copenhagen, Denmark) filed to raise up to $200 million in an IPO on NASDAQ underwritten by Leerink Partners. The company expects to trade under the symbol "FWP." Forward Pharma's lead product is …

    Published on 8/11/2014
  • FINANCIAL NEWS: Insmed planning $80 million follow-on

    Insmed Inc. (NASDAQ:INSM) proposed to raise up to $80 million in a follow-on underwritten by Leerink Partners; Piper Jaffray; JMP Securities; and H.C. Wainwright. Last Monday, Insmed fell $4.59 (27%) to $12.66 after …

    Published on 8/11/2014
  • FINANCIAL NEWS: Ligand planning $225M note deal, launches $200M buyback

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND) said late Monday it plans to raise $225 million through the sale of convertible senior notes due in 2019. Additionally, the company said its board has authorized a one-year $200…

    Published on 8/11/2014
  • FINANCIAL NEWS: Jazz raises $500 million in notes deal

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) raised $500 million through the sale of exchangeable senior notes to institutional investors. The notes bear 1.875% interest and mature Aug. 15, 2021. The notes initially convert …

    Published on 8/8/2014
  • FINANCIAL NEWS: MagForce subsidiary raises $15 million

    MagForce AG (Xetra:MF6) said its MagForce USA Inc. subsidiary raised $15 million through the sale of 1.5 million shares in the subsidiary at $10 in a "growth financing" round led by Mithril Capital Management. …

    Published on 8/8/2014
  • FINANCIAL NEWS: Tekmira soars on clinical hold conversion for TKM-Ebola

    Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) jumped $6.43 (45%) to $20.70 on NASDAQ and C$7.39 (47%) to C$23 in Toronto on Friday after announcing late Thursday that FDA converted to a partial hold a full …

    Published on 8/8/2014
  • FINANCIAL NEWS: Celladon amends follow-on

    Gene therapy play Celladon Corp. (NASDAQ:CLDN) said it now plans to sell 4 million shares in a follow-on. If sold at the company's close of $10.54 on Wednesday, before Celladon announced the amendment, the company would…

    Published on 8/7/2014
  • FINANCIAL NEWS: T2 raises $57M in IPO

    Diagnostics company T2 Biosystems Inc. (NASDAQ:TTOO) raised $57 million in its initial public offering of 5.2 million shares at $11 per share, valuing the company at $211.2 million. Goldman Sachs; Morgan Stanley; …

    Published on 8/7/2014
  • FINANCIAL NEWS: Tobira postpones IPO

    Infectious disease company Tobira Therapeutics Inc. (San Francisco, Calif.) postponed its IPO on NASDAQ, but did not disclose a reason. Last month, the company said it planned to sell 4.6 million shares at $12-$14. At …

    Published on 8/7/2014
  • FINANCIAL NEWS: Tolero raises $14.2 million in series B

    Tolero Pharmaceuticals Inc. (Lehi, Utah) raised $14.2 million in a series B round led by new investor Fred Alger Management and other undisclosed institutional and individual investors. Next year, Tolero plans to start …

    Published on 8/7/2014
  • FINANCIAL NEWS: Audiology company Auris unchanged in trading debut

    Auris Medical AG (NASDAQ:EARS) was unchanged at $6 on its first day of trading Wednesday after raising $56.4 million through the sale of 9.4 million shares at $6 in an IPO on Tuesday. Auris' esketamine (AM-101) is in …

    Published on 8/6/2014
  • FINANCIAL NEWS: Jazz to raise $500M in notes

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced after market close that it plans to raise $500 million from the sale of exchangeable senior notes to institutional investors. The senior notes are due in 2021 and are …

    Published on 8/6/2014
  • FINANCIAL NEWS: Walvax raises $72.8 million in private placement

    Vaccine play Walvax Biotechnology Co. Ltd. (SZSE:300142) raised RMB 450 million ($72.8 million) through the sale of 15.4 million shares at RMB29.27 in a private placement on Aug. 1. Walvax markets several vaccines for …

    Published on 8/6/2014
  • FINANCIAL NEWS: Auris prices IPO, to trade Wednesday

    Audiology company Auris Medical Holding AG (NASDAQ:EARS) raised $56.4 million through the sale of 9.4 million shares at $6 in an IPO. The price values the company at $169.4 million. Last month, Auris said it planned to …

    Published on 8/5/2014
  • FINANCIAL NEWS: TesoRx raises $10 million in series B-1

    TesoRx Pharma LLC (Menlo Park, Calif.) raised $10 million in a series B-1 round from undisclosed existing and new investors. TesoRx's TSX-002 is slated to begin Phase III testing in 1Q15 to treat hypogonadism. TSX-002 …

    Published on 8/5/2014
  • FINANCIAL NEWS: Enumeral raises $21.5M, reverse-merges

    Enumeral Biomedical Holdings Inc. (OTCQB:ENUM) reverse-merged with shell company Cerulean Group Inc. and began trading on the OTCQB. The immunotherapy company also raised $21.5 million through the sale of 21.5 million …

    Published on 8/4/2014
  • FINANCIAL NEWS: Evercore to acquire ISI

    Evercore Partners (NYSE:EVR) will acquire ISI and the 40% of Evercore's Institutional Equities Business that Evercore does not already own. In an email to clients, Mark Schoenebaum, head of ISI's healthcare research, …

    Published on 8/4/2014
  • FINANCIAL NEWS: Otonomy amends IPO

    Otonomy Inc. (San Diego, Calif.) amended its IPO on NASDAQ and now plans to sell 5.3 million shares at $14-$16. At the $15 midpoint, the company would raise $80 million and be valued at $291.3 million. Otonomy filed to …

    Published on 8/4/2014
  • FINANCIAL NEWS: Rebiotix raises $25 million in series B

    Infectious disease play Rebiotix Inc. (Roseville, Minn.) raised $25 million in a series B round from undisclosed existing and new investors. Rebiotix's RBX2660 is in the Phase II PUNCH CD trial to treat recurrent …

    Published on 8/4/2014
  • FINANCIAL NEWS: Gen9 raises $25 million in undisclosed venture round

    Synthetic biology company Gen9 Inc. (Cambridge, Mass.) raised $25 million from undisclosed investors in an undisclosed venture round. CEO Kevin Munnelly confirmed that the $25 million is in addition to a $21 million …

    Published on 8/1/2014
  • FINANCIAL NEWS: Loxo raises $68.4 million in IPO

    Loxo Oncology Inc. (NASDAQ:LOXO) raised $68.4 million through the sale of 5.3 million shares at $13 in a bumped-up IPO. The price values the company at $207.2 million. Last month, the company amended the offering to …

    Published on 8/1/2014
  • FINANCIAL NEWS: MacroCure raises $53.5 million in IPO

    Israeli biotech regenerative medicine company MacroCure Ltd. (NASDAQ:MCUR) raised $53.5 million through the sale of 5.4 million shares at $10 in an IPO underwritten by Credit Suisse; Jefferies; Nomura; and Oppenheimer. …

    Published on 8/1/2014
  • FINANCIAL NEWS: Avalanche skyrockets in trading debut

    Ophthalmic gene therapy play Avalanche Biotechnologies Inc. (NASDAQ:AAVL) jumped $10.99 (65%) to $27.09 on its first day of trading Thursday after raising $103 million through the sale of 6 million shares at $17 in an …

    Published on 7/31/2014
  • FINANCIAL NEWS: Bio Blast, Marinus, VBL take haircuts on IPOs

    Bio Blast Pharma Ltd. (NASDAQ:ORPN), Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) and Vascular Biogenics Ltd. (dba VBL Therapeutics Ltd.) (NASDAQ:VBLX) all took haircuts in IPOs on NASDAQ on Thursday. Bio Blast raised $35…

    Published on 7/31/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993